rTMS for normalizing Emotion Regulation in Substance Use Disorders Save

Date Added
October 21st, 2014
PRO Number
Pro00037704
Researcher
Brett Froeliger
Keywords
Brain, Central Nervous System, Mental Health, Nervous System, Psychiatry, Smoking, Substance Use
Summary

The purpose of this study is to use a treatment called repetitive Transcranial Magnetic Stimulation (rTMS) and brain imaging technique called functional magnetic resonance imaging (fMRI) to investigate the causes of depressive symptoms among nicotine dependent cigarette smokers. Participation in this study will involve 3 visits: a screening/training visit and 2 experimental visits. During the screening/training visit, you will provide biological samples to confirm your eligibility to participate and fill out questionnaires, learn the tasks that you will be performing on during the experimental visits, and become familiar with the tools you will be using and environment you will be in during the experimental visits. On each experimental visit, you will undergo fMRI scanning while performing the tasks practiced at training and receive either rTMS or a control rTMS treatment.

Institution
MUSC
Recruitment Contact
John LeMay
843-792-3084
lemay@musc.edu

Enhancing disrupted reconsolidation: Impact on cocaine craving, reactivity & use Save

Date Added
October 7th, 2014
PRO Number
Pro00021392
Researcher
Michael Saladin
Keywords
Drug Studies, Mental Health, Psychiatry, Substance Use
Summary

Our recently completed study has provided the first evidence that administration of the medication propranolol, following exposure to cocaine cues, can alter drug-associated memories and reduce craving and other drug cue-elicited responses in cocaine addicted persons. The proposed research will use two methods to increase the memory altering effects of propranolol observed in our recently completed study, and document lasting effects not only on craving and cue-elicited reactions, but also on cocaine use. Positive findings will set the stage for a formal clinical trial that could lead to significantly improved treatment outcomes for this treatment-resistant addiction.

Institution
MUSC
Recruitment Contact
Amanda Smith
843-792-6984
smitham@musc.edu

Augmenting Prolonged Exposure Therapy for PTSD with Intranasal Oxytocin Save

Date Added
September 2nd, 2014
PRO Number
Pro00036616
Researcher
Julianne Hellmuth
Keywords
Drug Studies, Healthy Volunteer Studies, Mental Health, Psychiatry, Stress Disorders
Summary

The main goal of current study is to compare changes in PTSD symptoms following Prolonged Exposure therapy (PE) combined with either a 40 IU dose of intranasal oxytocin or placebo. This will allow us to assess the potential benefits of augmenting PE with oxytocin. Prior to 8 of the 10 weekly therapy sessions (sessions 2-9), subjects will receive oxytocin or placebo.

Institution
MUSC
Recruitment Contact
Sudie Back
843-792-9383
backs@musc.edu

Longitudinal Study of Fearful Arousals Save

Date Added
September 2nd, 2014
PRO Number
Pro00018746
Researcher
Thomas Uhde
Keywords
Psychiatry, Sleep Disorders
Summary

The goal of this study is to document the phenomenology and longitudinal course of illness in patients with sleep panic disorder, narcolepsy (associated with fear-induced cataplexy), sleep paralysis, PTSD, nightmare disorder (not associated with PTSD), and sleep seizures disorders. Subjects will complete questionnaires, complete semi-structured interview, and be guided to complete a timeline of life events and illness episodes, etc. A second visit will ensure completion of timeline information and allow clinicians to have information to plot on a life chart to view the longitudinal course of illness.

Institution
MUSC
Recruitment Contact
Jennifer Runion
843-792-1752
runionj@musc.edu

Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study Save

Date Added
September 2nd, 2014
PRO Number
Pro00036485
Researcher
Zhewu Wang
Keywords
ADD/ADHD, Military, Psychiatry, Stress Disorders
Summary

Future Direction: The current available treatments for PTSD are not fully effective for cognitive symptoms of PTSD and have high drop-out and poor engagement, two factors found to be most indicative of overall return to functioning for patients with PTSD. Successful completion of this pilot clinical trial may build a platform for future large scale double-blind, placebo-controlled studies using either atomoxetine or psycho-stimulants or other cognitive enhancing medications. The response inhibition related measurements are sensitive to psychotropic medications. Therefore it is advantageous for us to use GNG and Stop Signal approaches to investigate individual treatments response in our future research. We believe GNG and Stop signal approaches together with pharmacogenetic approach will provide valuable information to direct future individualized medicine.

Institution
MUSC
Recruitment Contact
Howard Mandel
(843) 789-7104
mandelh@musc.edu

Treatment of Prolonged Grief Disorder in Combat Veterans Save

Date Added
September 2nd, 2014
PRO Number
Pro00036533
Researcher
Ronald Acierno
Keywords
Anxiety, Depression, Mental Health, Military, Psychiatry
Summary

The 'dual burden' of (a) loss of a fellow service member in the context of (b) experiencing repeated extreme life threat is unique to military combat personnel and a core characteristic of combat-related Prolonged Grief Disorder (PGD), a disorder as prevalent as Post-traumatic stress disorder and associated with functional impairment, disability, and suicidality. Effective treatments for depression and PTSD have proven less than adequate in treating PGD when each is offered in isolation; and simply combining these 12-16 week treatment regimens into a 24-36 week treatments is not a viable approach, particularly with a population predisposed to avoiding extended mental health care. The proposed project addresses the need for a Veteran/ military specific treatment of PGD, and uses technology to deliver this treatment in a format that is far more likely to be accepted by military personnel and Veterans. This study will impact clinical practice by providing the first evidence for effective treatment PGD in Veterans.

Institution
MUSC
Recruitment Contact
Stephanie Zeigler
(843) 789-6519
zeigls@musc.edu

National Network of Depression Centers Clinical Care Registry Save

Date Added
September 2nd, 2014
PRO Number
Pro00012855
Researcher
Constance Guille
Keywords
Depression, Metabolism, Post Partum Depression, Psychiatry
Summary

This study aims to establish a patient registry, collecting data in patients with mood disorders who are treated in routine clinical care at the participating centers in the National Network of Depression Centers (NNDC). Participants will be followed during the course (s) of their treatment. Data will be uploaded into the NNDC Data Coordinating Center database.

Institution
MUSC
Recruitment Contact
Constance Guille
843-792-6190
guille@musc.edu

A randomized placebo-controlled pilot trial of N-acetylcysteine in onychophagia Save

Date Added
August 5th, 2014
PRO Number
Pro00028506
Researcher
Amanda Roper
Keywords
Drug Studies, Healthy Volunteer Studies, Mental Health, Psychiatry
Summary

To conduct a study using N-acetylcysteine (NAC) in young adults who bite their fingernails in order to determine if this medication may assist in their quit attempts or help them to resist the urge to bite their fingernails.

Institution
MUSC
Recruitment Contact
Amanda Roper
843-792-4097
amp5@musc.edu

Cortical Excitability: Biomarker and Endophenotype in Combat Related PTSD Save

Date Added
August 5th, 2014
PRO Number
Pro00012134
Researcher
Zhewu Wang
Keywords
Healthy Volunteer Studies, Mental Health, Military, Psychiatry, Stress Disorders
Summary

The objective of the proposed study is to investigate the cortical excitability in combat related PTSD. To accomplish this objective, we will recruit combat veterans with and without PTSD. Clinical assessment will be performed to assess the severity of PTSD and combat exposure. A newly developed transcranial magnetic stimulation approach will be applied to examine the cortical excitability, then genetic analysis will be used to learn how genetic factors influence individual cortical excitability. We expect this innovative approach will enhance our knowledge about the mechnism of PTSD development.

Institution
MUSC
Recruitment Contact
Howard Mandel
843-789-7104
howard.mandel@va.gov

Exploring sex differences in the neural correlates of PTSD: Impact of oxytocin Save

Date Added
August 5th, 2014
PRO Number
Pro00019290
Researcher
Margaret Moran-santa maria
Keywords
Brain, Mental Health, Psychiatry
Summary

Although sex differences in brain development, structure and function are well known, few studies have explored how these differences contribute to risk and resilience to mental illness. Therefore, biomedical research studies investigating sex differences in brain physiology may lead to more effective intervention and treatment strategies.

Institution
MUSC
Recruitment Contact
Lisa Nunn
843-792-0476
jenkinli@musc.edu